The D3 -creatine dilution method non-invasively measures muscle mass in mice
- PMID: 37272263
- PMCID: PMC10410001
- DOI: 10.1111/acel.13897
The D3 -creatine dilution method non-invasively measures muscle mass in mice
Erratum in
-
Correction to: The D3-creatine dilution method non-invasively measures muscle mass in mice.Aging Cell. 2023 Dec;22(12):e13999. doi: 10.1111/acel.13999. Epub 2023 Oct 2. Aging Cell. 2023. PMID: 37781862 Free PMC article. No abstract available.
Abstract
Developing accurate methods to quantify age-related muscle loss (sarcopenia) could greatly accelerate development of therapies to treat muscle loss in the elderly, as current methods are inaccurate or expensive. The current gold standard method for quantifying sarcopenia is dual-energy X-ray absorptiometry (DXA) but does not measure muscle directly-it is a composite measure quantifying "lean mass" (muscle) excluding fat and bone. In humans, DXA overestimates muscle mass, which has led to erroneous conclusions about the importance of skeletal muscle in human health and disease. In animal models, DXA is a popular method for measuring lean mass. However, instrumentation is expensive and is potentially limited by anesthesia concerns. Recently, the D3 -creatine (D3 Cr) dilution method for quantifying muscle mass was developed in humans and rats. This method is faster, cheaper, and more accurate than DXA. Here, we demonstrate that the D3 Cr method is a specific assay for muscle mass in mice, and we test associations with DXA and body weight. We evaluated the D3 Cr method compared to DXA-determined lean body mass (LBM) in aged mice and reported that DXA consistently overestimates muscle mass with age. Overall, we provide evidence that the D3 Cr dilution method directly measures muscle mass in mice. Combined with its ease of use, accessibility, and non-invasive nature, the method may prove to more quickly advance development of preclinical therapies targeting sarcopenia.
Keywords: aging; mice; sarcopenia; skeletal muscle.
© 2023 The Authors. Aging Cell published by Anatomical Society and John Wiley & Sons Ltd.
Conflict of interest statement
The authors declare no conflicts of interest. Drs Hellerstein and Evans are listed as co‐inventors on the filed patents for the D3‐creatine dilution method; however, they do not derive any income related to commercial use of this method nor do they control the intellectual property.
Figures
References
-
- Kandutsch, A. A. , & Russell, A. E. (1958). Creatine and creatinine in tissues and urine of mice with hereditary muscular dystrophy. American Journal of Physiology, 194(3), 553–556. - PubMed
-
- Andrews, R. , Greenhaff, P. , Curtis, S. , Perry, A. , & Cowley, A. J. (1998). The effect of dietary creatine supplementation on skeletal muscle metabolism in congestive heart failure. European Heart Journal, 19(4), 617–622. - PubMed
-
- Cawthon, P. M. , Blackwell, T. , Cummings, S. R. , Orwoll, E. S. , Duchowny, K. A. , Kado, D. M. , Stone, K. L. , Ensrud, K. E. , Cauley, J. A. , & Evans, W. J. (2021). Muscle mass assessed by the D3‐Creatine dilution method and incident self‐reported disability and mortality in a prospective observational study of community‐dwelling older men. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 76(1), 123–130. - PMC - PubMed
-
- Cawthon, P. M. , Orwoll, E. S. , Peters, K. E. , Ensrud, K. E. , Cauley, J. A. , Kado, D. M. , Stefanick, M. L. , Shikany, J. M. , Strotmeyer, E. S. , Glynn, N. W. , Caserotti, P. , Shankaran, M. , Hellerstein, M. , Cummings, S. R. , Evans, W. J. , & Osteoporotic Fractures in Men (MrOS) Study Research Group . (2019). Strong relation between muscle mass determined by D3‐creatine dilution, physical performance, and incidence of falls and mobility limitations in a prospective cohort of older men. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 74(6), 844–852. - PMC - PubMed
